Cargando…

434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents

OBJECTIVES/GOALS: The goal of this project was to conduct a preliminary assessment of in vivo feasibility early on in the drug-discovery process in an effort to expedite the translation of novel drug scaffolds to potential clinical candidates. The data gathered in this study will be used to direct a...

Descripción completa

Detalles Bibliográficos
Autores principales: Furbish, Amelia B, Burger, Pieter, Peterson, Yuri K, Woster, Patrick M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209296/
http://dx.doi.org/10.1017/cts.2022.252
_version_ 1784729920942899200
author Furbish, Amelia B
Burger, Pieter
Peterson, Yuri K
Woster, Patrick M
author_facet Furbish, Amelia B
Burger, Pieter
Peterson, Yuri K
Woster, Patrick M
author_sort Furbish, Amelia B
collection PubMed
description OBJECTIVES/GOALS: The goal of this project was to conduct a preliminary assessment of in vivo feasibility early on in the drug-discovery process in an effort to expedite the translation of novel drug scaffolds to potential clinical candidates. The data gathered in this study will be used to direct analog synthesis of our current lead compounds through rational drug design. METHODS/STUDY POPULATION: Based on virtual and physical high-throughput screening efforts and subsequent similarity searching, we identified a set of potent and selective spermine oxidase (SMOX) inhibitors adhering to a common structural scaffold. In order to address potential barriers to in vivo use, we then conducted a robust optimization analysis in an effort to identify analogs with improved drug-like characteristics. Docking simulations to predict binding were performed and visualized using molecular modeling software (MOE and PyMol). ADMET properties were calculated using a variety of software resources including SwissADME and CDD Vault. RESULTS/ANTICIPATED RESULTS: Through these optimization efforts, we were able to successfully identify analogs with improved drug-like characteristics, including increases in predicted CNS penetration, isosteric replacement of metabolically labile functional groups, increased lipophilicity, and elimination of structural attributes suggestive of off-target activity. Analogs were ranked according to predicted binding and properties of in vivo feasibility. Compounds achieving the highest scores were then selected as scaffolds to guide analog synthesis. DISCUSSION/SIGNIFICANCE: Despite evidence implicating induction of SMOX as a mechanism contributing to neuronal pathology, the lack of potent and selective inhibitors with profiles conducive for in vivo use has significantly impeded clinical investigation of this target. In this presentation, rational drug design focusing on translational optimization will be discussed.
format Online
Article
Text
id pubmed-9209296
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-92092962022-07-01 434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents Furbish, Amelia B Burger, Pieter Peterson, Yuri K Woster, Patrick M J Clin Transl Sci Valued Approaches OBJECTIVES/GOALS: The goal of this project was to conduct a preliminary assessment of in vivo feasibility early on in the drug-discovery process in an effort to expedite the translation of novel drug scaffolds to potential clinical candidates. The data gathered in this study will be used to direct analog synthesis of our current lead compounds through rational drug design. METHODS/STUDY POPULATION: Based on virtual and physical high-throughput screening efforts and subsequent similarity searching, we identified a set of potent and selective spermine oxidase (SMOX) inhibitors adhering to a common structural scaffold. In order to address potential barriers to in vivo use, we then conducted a robust optimization analysis in an effort to identify analogs with improved drug-like characteristics. Docking simulations to predict binding were performed and visualized using molecular modeling software (MOE and PyMol). ADMET properties were calculated using a variety of software resources including SwissADME and CDD Vault. RESULTS/ANTICIPATED RESULTS: Through these optimization efforts, we were able to successfully identify analogs with improved drug-like characteristics, including increases in predicted CNS penetration, isosteric replacement of metabolically labile functional groups, increased lipophilicity, and elimination of structural attributes suggestive of off-target activity. Analogs were ranked according to predicted binding and properties of in vivo feasibility. Compounds achieving the highest scores were then selected as scaffolds to guide analog synthesis. DISCUSSION/SIGNIFICANCE: Despite evidence implicating induction of SMOX as a mechanism contributing to neuronal pathology, the lack of potent and selective inhibitors with profiles conducive for in vivo use has significantly impeded clinical investigation of this target. In this presentation, rational drug design focusing on translational optimization will be discussed. Cambridge University Press 2022-04-19 /pmc/articles/PMC9209296/ http://dx.doi.org/10.1017/cts.2022.252 Text en © The Association for Clinical and Translational Science 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Valued Approaches
Furbish, Amelia B
Burger, Pieter
Peterson, Yuri K
Woster, Patrick M
434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents
title 434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents
title_full 434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents
title_fullStr 434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents
title_full_unstemmed 434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents
title_short 434 In silico ADMET optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents
title_sort 434 in silico admet optimization and preliminary biologic activity of novel spermine oxidase inhibitors as neuroprotective agents
topic Valued Approaches
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209296/
http://dx.doi.org/10.1017/cts.2022.252
work_keys_str_mv AT furbishameliab 434insilicoadmetoptimizationandpreliminarybiologicactivityofnovelspermineoxidaseinhibitorsasneuroprotectiveagents
AT burgerpieter 434insilicoadmetoptimizationandpreliminarybiologicactivityofnovelspermineoxidaseinhibitorsasneuroprotectiveagents
AT petersonyurik 434insilicoadmetoptimizationandpreliminarybiologicactivityofnovelspermineoxidaseinhibitorsasneuroprotectiveagents
AT wosterpatrickm 434insilicoadmetoptimizationandpreliminarybiologicactivityofnovelspermineoxidaseinhibitorsasneuroprotectiveagents